Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-311-3 | CAS number: 57-09-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- other: published study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: The published study is well described. The study was not performed according to GLP and no guideline was given.
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 1 975
Materials and methods
- Objective of study:
- toxicokinetics
- Principles of method if other than guideline:
- The absorption, distribution and excretion of orally administrered radiolabelled cetyltrimethylammonium bromide in rats.
- GLP compliance:
- not specified
- Remarks:
- Performed before GLP guideline
Test material
- Reference substance name:
- Hexadecyltrimethylammonium bromide
- Cas Number:
- 57-09-0
- IUPAC Name:
- Hexadecyltrimethylammonium bromide
- Test material form:
- not specified
Constituent 1
- Specific details on test material used for the study:
- - Name of test material (as cited in study report): [14C] CTAB, Cetyltrimethylammonium bromide
- Radiochemical purity (if radiolabelling): 99%
- Specific activity (if radiolabelling): 17.6 µCi/mg
- Locations of the label (if radiolabelling): [1-14C]cetyl - Radiolabelling:
- yes
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- - Weight at study initiation: 210-240 g
- Fasting period before study: 24 hours
- Individual metabolism cages: For excretion study
- Diet (e.g. ad libitum): After 8 hours for experiments lasting more than 24 hours
- Water (e.g. ad libitum): After 8 hours for experiments lasting more than 24 hours
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- An aqueous solution of 0.8 mg/kg radiolabelled CTAB was given by gastric intubation in volumes of 4.0 ml/kg body weight.
- Duration and frequency of treatment / exposure:
- The animals were killed 2, 4, 8, 25, 48, 72 and 96 hours after intubation.
Doses / concentrations
- Remarks:
- Doses / Concentrations:
4.0 ml/kg bw of an aqueous solution of radiolabelled CTAB (0.8 mg/kg): 3.2 µg/kg bw
- Details on dosing and sampling:
- Distribution study: Blood samples were withdrawn from the tail before the animals were killed. The animals were killed 2, 4, 8, 25, 48, 72 and 96 hours after intubation. Tissue samples of liver, kidney, spleen, heart, lungs and hind leg were taken from the killed animal. In animals killed 8 hours after intubation, the gastro-intestinal tract was removed and divided into stomach, proximal and distal halves of the small intestine and the caecum and colon together.
Excretion study: Animals were kept in metabolism cages in order to collect urine and faeces in 4 hours interval for 3 days. Expired CO2 was trapped in NaOH at 4 hours interval during day 1 after intubation. Bile was collected for 12 hours at 2 hours interval
Results and discussion
Toxicokinetic / pharmacokinetic studies
- Details on distribution in tissues:
- A total of about 80% of the administered radioactivity was found in the gastro-intestinal tract mostly being in the gastro-intestinal contents. About 90% of the dose had left the stomach within 8 hours. Only small amounts of the radioactivity were found in tissues of other organs indicating that the CTAB is not preferentially distributed to any single target organ. Liver and kidneys showed highest level of radioactivity with a peak level in liver of 0.8% of the administered dosae occurring 8 hours after dosing. The tissue radioactivity declined rapidly and only traces were found 4 days after dosing.
- Details on excretion:
- About 2% of the administered dose was excreted in the bile during the first 12 hours after administration. This indicated together with low levels in the serum poor intestinal absorption of CTAB. After 3 days of the oral administration, the excretion in faeces was 92% and in urine 1% of the administered dose. Most of the radioactivity excreted in the faeces is suggeted to be unabsorbed material. No radioactivity was found in the expired CO2 collected during day 1.
Metabolite characterisation studies
- Metabolites identified:
- no
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): no bioaccumulation potential based on study results
A total of about 80% of the administered radioactivity was found in the gastro-intestinal tract 8 hours of oral administration. The findings together with low levels of radioactivity in the serum and bile indicated that CTAB is poorly absorbed in the gastro-intestinal tract. After 3 days of the oral administration, the excretion in faeces was 92% and in urine 1% of the administered dose. Most of the radioactivity excreted in the faeces is suggested to be unabsorbed material. Only small amounts of radioactivity were found in the blood and in tissues of organs other than the gastro-intestinal tract indicating that the CTAB is not preferentially distributed to any single target organ.
These data indicate that at least 3% of the oral dose have been systimally absorbed as this was the amount that had been found to be excreted through bile + urine. As further 6% of the radioactivity could not be accounted for a maximum absorption rate of 9% can be assumed. Thus for further risk assessment pupose an average oral absorption rate of 6% is used. - Executive summary:
The reported study examines the excretion and distribution of radiolabelled cetyltrimethylammonium bromide orally administered in female rats.
About 80% of the administered radioactivity was found in the gastro-intestinal tract 8 hours after oral administration. Only small amounts were found in the blood and plasma and about 2% of the administered radioactivity was excreted in the bile during the first 12 hgours. After 3 days the total excretion in faeces was 92% and in urine 1% of the administered dose. The findings together with low levels of radioactivity in the serum and bile indicated that CTAB is poorly absorbed in the gastro-intestinal tract. Most of the radioactivity excreted in the faeces is suggested to be unabsorbed material. Only small amounts of radioactivity were found in the blood and in tissues of organs other than the gastro-intestinal tract indicating that the CTAB is not preferentially distributed to any single target organ. These data indicate that approximately 3% of the oral dose have been systimally absorbed as this was the amount that had been found to be excreted through bile + urine.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.